Sleep-related eating disorder and night eating syndrome: Sleep disorders, eating disorders, or both?

Sleep (Impact Factor: 4.59). 08/2006; 29(7):876-7.
Source: PubMed
Download full-text


Available from: John Winkelman, Nov 05, 2015
  • Source
    • "As her medication list shows, she was already on topiramate for her migraine headache which was continued after stopping quetiapine. Although topiramate has been shown to be effective in SRED in a small trial [2], it did not help in her SRED symptoms. We tapered and eventually stopped her quetiapine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Somnambulism or sleepwalking is a disorder of arousal from non-rapid eye movement sleep. The prevalence of sleep-related eating disorder has been found to be approximately between 1% and 5% among adults. Many cases of medication-related somnambulism and sleep-related eating disorder-like behavior have been reported in the literature. Quetiapine, an atypical antipsychotic medication, has been associated with somnambulism but has not yet been reported to be associated with sleep-related eating disorder. Case presentation Case 1 is a 51-year-old obese African American male veteran with a body mass index of 34.11kg/m2 and severe sleep apnea who has taken 150mg of quetiapine at bedtime for more than one year for depression. He developed sleepwalking three to four nights per week which resolved after stopping quetiapine while being compliant with bi-level positive pressure ventilation therapy. At one year follow-up, his body mass index was 32.57kg/m2. Case 2 is a 50-year-old African American female veteran with a body mass index of 30.5kg/m2 and mild sleep apnea who has taken 200mg of quetiapine daily for more than one year for depression. She was witnessed to sleepwalk three nights per week which resolved after discontinuing quetiapine while being treated with continuous positive airway pressure. At three months follow-up, her body mass index was 29.1kg/m2. Conclusion These cases illustrate that quetiapine may precipitate complex motor behavior including sleep-related eating disorder and somnambulism in susceptible patients. Atypical antipsychotics are commonly used in psychiatric and primary care practice, which means the population at risk of developing parasomnia may often go unrecognized. It is important to recognize this potential adverse effect of quetiapine and, to prevent injury and worsening obesity, discuss this with the patients who are prescribed these medications.
    Journal of Medical Case Reports 11/2012; 6(1):380. DOI:10.1186/1752-1947-6-380
  • Source
    • "The sleep of individuals with SMI is often disturbed (Monti and Monti, 2005), which could increase the likelihood of nocturnal ingestions of food. Sleep disturbance also increases the likelihood that an individual will be prescribed psychotropic medications (e.g., hypnotics) known to increase nocturnal eating with limited awareness (i.e., Sleep-related Eating Disorder; Winkelman, 2006). In the current study, however, participants must have reported awareness of nocturnal ingestions of food to be a considered NES positive, and all but one participant who endorsed nocturnal ingestions of food reported some degree of awareness while eating. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of night eating syndrome (NES) and binge eating disorder (BED) was assessed among overweight and obese, weight-loss-seeking individuals with serious mental illness (SMI). Sixty-eight consecutive overweight (BMI > or = 25 kg/m(2)) and obese (BMI > or = 30 kg/m(2)) individuals with SMI (mean age = 43.9 years; mean BMI = 37.2 kg/(2); 67.6% Caucasian, 60.3% female) who were enrolled in a group behavioral weight loss treatment program were assessed at baseline for NES and BED with clinician-administered diagnostic interviews. Using conservative criteria, 25.0% met criteria for NES, 5.9% met criteria for BED, and only one participant met criteria for both NES and BED. This is the first study to find that obese individuals with SMI, compared with previously studied populations, are at significantly greater risk for NES, but are not at greater risk for BED. Stress, sleep, and medication use might account for the high prevalence of NES found in this population.
    Psychiatry Research 02/2010; 175(3):233-6. DOI:10.1016/j.psychres.2008.10.027 · 2.47 Impact Factor
  • Source
    • "Even though differences have been described between SRED and NES, there are also overlapping features which led Schenck (2006) to suggest that the two syndromes 'may exist along a shared spectrum of pathophysiology'. Winkelman (2006) even stated that it is 'unclear whether NES and SRED are the same or distinct disorders'. SREDs have been shown to be associated with a variety of underlying sleep disorders such as somnambulism, periodic limb movement disorder (PLMD), restless legs syndrome (RLS) and OSAS (10–14%) (Schenck, Hurwitz, Bundlie, & Mahowald, 1991; Schenck, Hurwitz, O'Connor, & Mahowald, 1993; Schenck & Mahowald, 1994; Winkelman, 1998; Vetrugno, Manconi , Ferini-Strambi, Provini, Plazzi, & Montagna, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to explore the nature and extent of the association between night eating, other forms of disordered eating and obstructive sleep apnea (OSAS).Eighty-one participants (20 women and 61 men), mean age 53.7 years diagnosed with OSAS were assessed prior to starting treatment. Using a cut-off of > or =25 on the Night Eating Questionnaire (NEQ), 8.6% of the participants screened positive for night eating syndrome (NES). In addition, 7.5% met criteria for a daytime eating disorder. NES was significantly associated with diagnoses of depression, anxiety and eating disorders and was significantly correlated with an impairment of mental quality of life. No associations were found between NES and gender, BMI and the severity of the OSAS. NES does not appear to be closely linked to OSAS; however, in patients with OSAS and NES a significant co-morbidity with psychiatric disorders can be expected which might require additional treatment.
    European Eating Disorders Review 03/2009; 17(2):120-7. DOI:10.1002/erv.908 · 2.46 Impact Factor
Show more